Work

Eteplirsen, a Phosphorodiamidate morpholino oligomer (PMO) for the treatment of Duchenne muscular dystrophy (DMD): Clinical update

Year: 2015

Type: article

Study design: Clinical Trial

Source: Neuromuscular Disorders

DOI: 10.1016/j.nmd.2015.06.282

Authors: E. Kaye, J. Mendell, L. Rodino-Klapac, Z. Sahenk, L. Lowes, L. Alfano, K. Berry, A. Gomez Ramirez, S. Lewis, K. Flanigan, L. Cripe, S. Al-Zaidy, P. Duda, P. Sazani, J. Saoud

Institutions: Sarepta Therapeutics (United States), Nationwide Children's Hospital

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2509502196

FWCI:

Cites:

Cited by: 2

Related to: 10